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Purpose/objectives: Multiparametric advanced MR and [18F]fluorodeoxyglucose 
(FDG)-positron emission tomography (PET) imaging may be important biomarkers for 
prognosis as well for distinguishing recurrent glioblastoma multiforme (GBM) from treat-
ment-related changes.
Methods/materials: We retrospectively evaluated 30 patients treated with chemora-
diation for GBM and underwent advanced MR and FDG-PET for confirmation of tumor 
progression. Multiparametric MRI and FDG-PET imaging metrics were evaluated for 
their association with 6-month overall (OS) and progression-free survival (PFS) based on 
pathological, radiographic, and clinical criteria.
results: 17 males and 13 females were treated between 2001 and 2014, and later 
underwent FDG-PET at suspected recurrence. Baseline FDG-PET and MRI imaging 
was obtained at a median of 7.5 months [interquartile range (IQR) 3.7–12.4] follow-
ing completion of chemoradiation. Median follow-up after FDG-PET imaging was 
10 months (IQR 7.2–13.0). Receiver-operator characteristic curve analysis identified 
that lesions characterized by a ratio of the SUVmax to the normal contralateral brain 
(SUVmax/NB index) >1.5 and mean apparent diffusion coefficient (ADC) value of 
≤1,400 × 10−6 mm2/s correlated with worse 6-month OS and PFS. We defined three 
patient groups that predicted the probability of tumor progression: SUVmax/NB index 
>1.5 and ADC ≤1,400 × 10−6 mm2/s defined high-risk patients (n = 7), SUVmax/NB 
index ≤1.5 and ADC >1,400 ×  10−6 mm2/s defined low-risk patients (n =  11), and 
intermediate-risk (n = 12) defined the remainder of the patients. Median OS following 
the time of the FDG-PET scan for the low, intermediate, and high-risk groups were 
23.5, 10.5, and 3.8 months (p < 0.01). Median PFS were 10.0, 4.4, and 1.9 months 
(p = 0.03). Rates of progression at 6-months in the low, intermediate, and high-risk 
groups were 36, 67, and 86% (p = 0.04).
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conclusion: Recurrent GBM in the molecular era is associated with highly variable 
outcomes. Multiparametric MR and FDG-PET biomarkers may provide a clinically rel-
evant, non-invasive and cost-effective method of predicting prognosis and improving 
clinical decision making in the treatment of patients with suspected tumor recurrence.
Keywords: radiation, Mri, apparent diffusion coefficient, diffusion, [18F]fluorodeoxyglucose-positron emission 
tomography, glioblastoma, radionecrosis
inTrODUcTiOn
Although significant advancements in the treatment of glio-
blastoma multiforme (GBM) have occurred in recent decades, 
survival outcomes remain poor. The median survival is approxi-
mately 12–15 months (1) and tumor progression is inevitable for 
most patients. In the post-treatment setting, treatment-induced 
changes can confound definitive identification of tumor recur-
rence and progression (2, 3). Differentiating tumor progression 
from post-treatment radiographic changes, including radi-
onecrosis, is vital to provide patients with appropriate salvage 
therapies to extend life and avoid unnecessary toxicity for those 
without evidence of disease. The advent of new modalities to 
detect tumor progression earlier in the surveillance period may 
translate to improved survival for patients with GBM.
Assessing GBM response to therapy has been a challenging 
and controversial aspect of post-treatment oncologic manage-
ment. Current National Comprehensive Cancer Network 
guidelines for GBM treatment response surveillance recommend 
conventional brain MRI 2–6 weeks after radiation therapy, fol-
lowed by MRI every 2–3 months for the next 2–3 years, and less 
frequent imaging thereafter (4). Although diffusion and perfusion 
imaging using MRI have demonstrated their ability to differenti-
ate recurrence from radiation necrosis (5–7), there remains no 
gold standard imaging technique to diagnose recurrent disease 
in GBM patients. The recently published Response Assessment 
in Neuro-Oncology Criteria (RANO) criteria improved the 
accuracy of follow-up imaging; however, identification of tumor 
progression remains a formidable challenge (8).
In addition to MRI, positron emission tomography (PET) 
imaging has shown promise in the identification of GBM tumor 
progression (9–11). PET using [18F]fluorodeoxyglucose (FDG-
PET) is a well-established imaging technique for evaluation of 
treatment response in other cancers; however, its use in GBM 
surveillance remains controversial, especially given high baseline 
cerebral FDG uptake (12–16). In addition to PET imaging, stud-
ies have shown the utility of magnetic resonance spectroscopy 
(MRS) to predict tumor recurrence (17), and a meta-analysis 
found that MRS alone had modest diagnostic performance in 
identifying recurrent tumor (18). Although several studies have 
investigated the ability of FDG-PET to differentiate radionecro-
sis from true progression, few have investigated the prognostic 
implications of integrated FDG-PET and MR parameters on 
patient outcomes (19).
We hypothesized that a combination of FDG-PET and MR 
imaging parameters could be used to develop a risk stratifica-
tion system to better identify patients with GBM recurrence. 
The objective of this study was to evaluate a cohort of patients 
with GBM with suspected recurrence and to determine optimal 
imaging parameters using FDG-PET and multiparametric MRI 
that could be used to predict outcomes.
MaTerials anD MeThODs
study Population
We retrospectively identified 30 patients with pathologically 
confirmed GBM (WHO grade IV) who received treatment 
consisting of biopsy or surgery, external beam radiation therapy, 
and concurrent and adjuvant temozolomide (1) between 2001 
and 2014; and subsequently developed an enhancing lesion on 
conventional contrast-enhanced MRI that was presumed to be 
suspicious, but not definitive, for tumor progression according 
to the RANO Criteria (8) and review at multidisciplinary tumor 
board. These patients were initially identified from our institu-
tion’s medical record to include all patients who underwent the 
treatment regimen as described above in addition to undergo-
ing a FDG-PET/CT scan. All patients received a brain FDG-
PET/CT scan between 2007 and 2015 to evaluate for treatment 
effect versus true progression. This retrospective analysis was 
approved by the Washington University Institutional Review 
Board.
Mri and PeT imaging Technique
Baseline MRI and FDG-PET scans were obtained at the time of 
suspected progression. Twenty-eight of the patients underwent 
separate 1.5  T MRI (Sonata or Symphony; Siemens, Erlangen, 
Germany) and hybrid FDG-PET/CT scans (Biograph Duo 
or LSO-40; Siemens, Erlangen, Germany), while two patients 
received simultaneous 3  T-MRI/PET acquisition on a hybrid 
PET/MR scanner (Siemens mMR PET/MR; Siemens, Erlangen, 
Germany). The patients underwent brain tumor protocol MR 
imaging (20) before and after intravenous gadolinium contrast. 
MR sequences included T1-weighted (pre-and post contrast), 
T2-weighted, fluid attenuation inversion recovery (FLAIR), and 
diffusion-weighted imaging. Dynamic susceptibility contrast 
(DSC) perfusion-weighted imaging was performed using a 
gradient-echo echoplanar imaging sequence during the first pass 
of gadobenate dimeglumine (MultiHance; Bracco Diagnostics, 
Princeton, NJ, USA) or gadoversetamide (Optimark; Guerbet, 
Paris, France) at a dose of 0.1 mmol/kg. Images were acquired 
at 1 s intervals with intravenous contrast medium injected at a 
rate of 5 mL/s followed by a 20 mL bolus of saline at the same 
injection rate beginning on image 10. Perfusion-weighted imag-
ing was processed in all patients for which imaging was acquired 
and available in the clinical PACS archive. FDG-PET images 
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were obtained beginning 30–67  min (median, 41.5  min) after 
the administration of 4.4–16.6 mCi FDG (median 10.01 mCi), 
dosed per the patient’s weight as per standard PET protocol. Non-
contrast CT imaging was acquired for attenuation correction and 
anatomic localization. The median time between the baseline 
MRI and FDG-PET was 7 days (range, 0–25 days). The MRI and 
PET images were typically obtained within 3–5 days of each other, 
while four patients had longer intervals of greater than 2 weeks.
PeT and Mr imaging analysis
Imaging data were retrospectively post-processed and co-regis-
tered based upon cranial anatomy using MIMVista 5 software 
(MIMVista Corp., Cleveland, OH, USA). Axial T1-weighted 
gadolinium-enhanced imaging was used to define the region 
of interest (ROI) by a fellowship-trained neuroradiologist. All 
patient imaging was processed if clinically acquired and available 
in the institutional PACS database.
Cerebral blood volume (CBV) maps were calculated from the 
DSC perfusion data using syngo.Via Neuro Perfusion software 
(Siemens, Erlangen, Germany) with automated selection of the 
arterial input function and correction for vascular permeability. 
CBV were recorded within the ROI identified on contrast-
enhanced T1-weighted imaging and in the contralateral normal 
appearing brain ROI. Subsequently, a ratio of the CBV in the 
ROI to the contralateral normal CBV was calculated to derive the 
relative cerebral blood volume (rCBV). Mean apparent diffusion 
coefficient (ADC) values were analyzed within the ROI.
[18F]fluorodeoxyglucose-positron emission tomography ROI 
were defined by a combination of automatic thresholding using 
a 40% threshold value of the tumor SUVmax as well as further 
manual editing by the nuclear medicine physician upon review 
of the corresponding T1-weighted and FLAIR MR imaging for 
anatomic reference. The threshold value was chosen based on 
previous publications of high-grade glioma (21) and extracranial 
tumors (22, 23). To obtain a normalized quantity for FDG uptake 
in the region of suspected recurrence, a reference contour was 
placed on a region of normal frontal or parietal lobe normal 
brain (NB) contralateral to the corresponding lesion ROI. The 
normal brain ROI was outside of the 20 Gy isodose line in the 
radiation treatment plan. The normalized quantity was defined as 
the SUVmax/NB index. Maximum standard uptake value (SUVmax), 
SUVmin, SUVmean, metabolic tumor volume, total lesion glycolysis, 
and SUVmean of the contralateral normal brain matter reference 
ROI were recorded from the FDG-PET imaging.
Follow-up analysis
Patients typically underwent MR imaging every 2–3 months after 
completion of chemoradiation therapy and more frequently if 
clinically indicated. Additional treatment and use of bevacizumab, 
particularly prior to baseline imaging, was recorded. Additional 
treatments after baseline imaging (including use of bevacizumab) 
until last follow-up or death were also recorded.
Patients were retroactively scored on whether they had true 
progression versus treatment effect in the following manner: 
patients were scored as having a true progression if they had 
(i) histopathologic confirmation of residual or recurrent malig-
nant glioma within 6 months of baseline imaging (pathological 
progression), (ii) two subsequent MRI scans with progressively 
enlarging tumor within 6 months of baseline imaging according 
to the RANO criteria (radiologic progression), or (iii) death due 
to GBM prior to 6 months of follow-up after baseline imaging 
(clinical progression). Patients were retroactively scored as hav-
ing treatment effect at the time of baseline imaging if not meeting 
pathologic, radiologic, or clinical progression criteria within 
6 months of the imaging. This composite system has previously 
been used by other groups to retroactively score for progression 
versus treatment effect after radiosurgery for brain metastases 
and, therefore, we adopted it for use in this study (24).
statistical analysis
In addition to true progression versus treatment effect, additional 
outcome measures for this study were progression-free survival 
(PFS), and overall survival (OS). Dichotomization of imaging 
parameters were performed for distinguishing treatment effect 
versus true progression using receiver-operator characteristic 
curve (ROC) analysis. The threshold with the maximum sensitiv-
ity plus specificity from the ROC analysis was selected. Survival 
analyses were performed using the Kaplan–Meier method and 
log-rank statistical test. PFS was defined as the time until the 
earliest of (i) date of pathologically confirmed progression, (ii) 
the earlier of the two sequential MRI scans interpreted as progres-
sion, or (iii) date of death. OS was defined as the time from the 
PET scan until death, censoring at last follow-up for those who 
were alive. These survival estimates were calculated from the time 
of the FDG-PET scan in the primary analysis and confirmed after 
survival estimates were re-calculated from the time of surgery. 
The Cox proportional hazards model was used in univariate 
analyses of all parameters. χ2 or ordinal χ2 testing was performed 
as appropriate. Multivariate analysis was not performed due to 
small number of patients and a large number of correlated imag-
ing parameters. Significance was considered at a value of p < 0.05. 
All levels of significance were two-sided. SPSS version 22.0 was 
used for all statistical analyses.
resUlTs
Patient characteristics
A total of 30 patients were identified using the inclusion cri-
teria. The mean patient age was 52.1  years (range, 21–75) and 
17 were male (56.7%). Baseline MRI imaging was acquired at a 
median time of 7.5 months [range, 0.5–116; interquartile range 
(IQR), 3.7–12.4] after completion of adjuvant chemoradiation. 
Baseline PET was obtained at a median of 7 days after baseline 
MRI imaging. Overall, the median follow-up was 20.8  months 
(range, 6.6–133; IQR, 15.5–33.4), and the median follow-up 
after baseline PET scan was 10 months (range, 1.3–32.8 months; 
IQR, 7.2–13.0). IQRs in addition to range are provided for these 
intervals as one patient had a very long remission between initial 
treatment and recurrence, which greatly increased the upper 
range. O6-methylguanine-DNA methyltransferase (MGMT) was 
methylated in 10 patients, non-methylated in 11 patients, and 
unknown in 9 patients. Isocitrate dehydrogenase 1 (IDH1) R132 
mutation was present in 2 patients, wild type in 21 patients, and 
unknown in 7 patients. Surgery involved gross total resection in 
TaBle 1 | Patient and tumor characteristics.
Total number of patients 30
Median FU after diagnosis (IQR) 20.8 months (15.5–33.4)
Median FU after PET (IQR) 10.0 months (7.2–13.0)



















Unknown status 7 30
iDh1 (r132) mutation
Wild type 21 66
Mutated 2 6





Previous progression before PeT and Mri
No (first suspected progression) 22 73
Yes 8 26
Other treatment before PeT and Mri
None (other than initial surgery, RT, and TMZ) 10 33
Chemotherapy 18 60
Surgery 2 7
Use of bevacizumab before PeT and Mri
No 24 80
Yes 6 20





Use of bevacizumab after PeT and Mri
No 10 33
Yes 20 67
FU, follow-up; KPS, Karnofsky performance score; MGMT, O6-methylguanine-DNA 
methyltransferase; IDH, isocitrate dehydrogenase; GTR, gross total resection; STR, 
subtotal resection; NTR, near total resection; IQR, interquartile range; PET, positron 
emission tomography; RPA, recursive partitioning analysis; TMZ, temozolomide.
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16 patients, subtotal resection (STR) or near total resection in 
12 patients, and biopsy alone in 2 patients. External beam radia-
tion dose was 59.4–63 Gy for all patients. All patients received 
concurrent and adjuvant temozolomide. Bevacizumab was 
given as a part of the treatment course in six patients prior to 
the patient undergoing both PET and MR imaging. Additional 
patient, tumor, and treatment characteristics are listed in Table 1. 
Representative ROI used in the analyses are shown in Figure 1.
FigUre 1 | Continued
Follow-up
Four patients had pathologic confirmation of progression versus 
treatment effect within 6 months of baseline imaging. Pathology 
revealed recurrent tumor in two patients, radiation necrosis in one 
patient and extensive treatment effect mixed with small amounts 
of glioma in one patient. Pathology was obtained at a median 
of 3.1 months after baseline PET scan (range, 1.0–4.3 months). 
In the remaining 26 patients, based on the follow-up criteria, 15 
patients were scored as having true recurrence and 11 patients 
were scored as treatment effect.
TaBle 2 | Univariate analyses of PFS and OS.
UVa for PFs after PeT UVa for Os after PeT
hr (95% ci) p hr (95% ci) p
sex
Male Reference Reference
Female 0.40 (0.17–0.97) 0.04 0.48 (0.19–1.20) 0.12
Age 1.01 (0.98–1.04) 0.69 1.01 (0.98–1.05) 0.51
race
White Reference Reference
Black 1.87 (0.42–8.31) 0.41 2.24 (0.50–10.07) 0.29
Other 2.26 (0.29–17.70) 0.44 2.51 (0.32–19.89) 0.38
KPs at diagnosis
≤70 Reference Reference
80–100 0.64 (0.26–1.60) 0.34 0.64 (0.24–1.69) 0.37
rPa class
III Reference Reference
IV 1.98 (0.37–10.37) 0.42 1.90 (0.36–10.04) 0.42
V 1.26 (0.29–5.51) 0.77 0.94 (0.21–4.23) 0.93
MgMT methylation
Non-methylated Reference Reference
Methylated 0.17 (0.05–0.56) <0.01 0.15 (0.03–0.67) 0.01
surgery
GTR Reference Reference
STR/NTR 1.56 (0.35–7.03) 0.56 0.33 (0.07–1.72) 0.19
Biopsy 0.82 (0.34–1.98) 0.65 0.49 (0.11–2.24) 0.36
Previous progression before PeT
No Reference Reference
Yes 1.18 (0.46–3.02) 0.73 1.56 (0.59–4.14) 0.37
Other treatment before PeT
None Reference Reference
Chemotherapy 0.75 (0.31–1.81) 0.52 2.86 (0.92–9.04) 0.07
Surgery 0.75 (0.16–3.60) 0.72 1.30 (0.26–6.57) 0.41
Mri parameters
Mean ADC 0.998 (0.997–1.000) 0.056 0.998 (0.997–1.000) 0.064
rCBV 1.42 (0.79–2.56) 0.25 2.19 (0.953–5.03) 0.7
aDc cut-point
≤1,400 Reference Reference
>1,400 0.34 (0.12–0.92) 0.03 0.29 (0.08–0.99) 0.048
PeT parameters
SUVmax 1.04 (0.94–1.16) 0.42 1.07 (0.98–1.19) 0.23
SUVmin 1.07 (0.80–1.43) 0.66 0.99 (0.68–1.45) 0.99
SUVmean 1.15 (1.01–1.30) 0.03 1.13 (1.01–1.27) 0.03
MTV 0.98 (0.93–1.03) 0.39 1.01 (0.96–1.05) 0.81
TLG 1.00 (0.99–1.01) 0.92 1.003 (0.998–1.008) 0.32
SUVmax/NB index 1.63 (1.10–2.43) 0.02 4.53 (1.10–18.7) 0.04
sUVmax/nB index cut-point
≤1.5 Reference Reference
>1.5 3.48 (1.35–8.98) 0.01 4.65 (1.71–12.65) <0.01
risk groups
Low Reference Reference
Intermediate 2.05 (0.76–5.57) 0.16 1.73 (0.53–5.70) 0.37
High 4.08 (1.33–12.42) 0.01 6.41 (1.81–22.75) <0.01
salvage treatment after PeT
None Reference Reference
Chemotherapy 2.48 (0.32–19.31) 0.39 5.30 (0.52–54.2) 0.16
Radiation 0.78 (0.05–12.78) 0.86 1.40 (0.08–15.20) 0.82
Surgery 1.00 (0.11–9.04) 0.98 1.82 (0.18–18.42) 0.61
MTV, metabolic tumor volume (cubic centimeters); TLG, total lesion glycolysis (cubic 
centimeters); NB, normal brain; ADC, apparent diffusion coefficient (×10−6 mm2/s); 
rCBV, relative cerebral blood volume; PFS, progression-free survival measured from 
date of FDG-PET scan; OS, overall survival measured from date of FDG-PET scan; 
GTR, gross total resection; STR/NTR, subtotal resection or near total resection; FDG, 
[18F]fluorodeoxyglucose; PET, positron emission tomography; HR, hazard ratio; KPS, 
Karnofsky performance score; RPA, recursive partitioning analysis.
p-Values in bold denote statistically significant associations.
FigUre 1 | Continued  
Representative patients in the study who were classified as high risk and low 
risk at the time of imaging. (a) The patient was a 36-year-old male who had 
MGMT non-methylated, isocitrate dehydrogenase 1 (IDH1) wild-type 
multifocial glioblastoma multiforme of the right temporal lobe at diagnosis, 
and received biopsy, radiation therapy to 63 Gy with concurrent 
temozolomide, followed by adjuvant temozolomide and bevacizumab therapy 
for 13 months prior to this MRI and [18F]fluorodeoxyglucose (FDG)-positron 
emission tomography (PET) scan. The tumor had a SUVmax of 11.64, a 
SUVmax/NB ratio of 2.00, and an apparent diffusion coefficient (ADC) of 
1,031 × 10−6 mm2/s. He was classified as high risk and treated with erlotinib. 
He developed further progression on imaging after 1 month. This patient died 
of disease at 2 months after this FDG-PET scan. The top two panels show 
axial slices of the FDG-PET scan at the level of the tumor (left) and normal 
brain (right). The bottom two panels show axial slices of the T1 contrast 
image at the level of the tumor (left) and normal brain (right). Red represents 
tumor region of interest used for deriving imaging parameters. Green 
represents contralateral uninvolved gray matter for normalizing SUVmax.  
(B) The patient is a 37-year-old female who had MGMT methylated, 
IDH1-mutated glioblastoma multiforme of the left temporal lobe treated  
with gross total resection, radiation therapy to 60 Gy with concurrent 
temozolomide, followed by adjuvant temozolomide with a tumor treating 
fields device (Novocure Optune) for 5 months prior to this MRI and FDG-PET 
scan. The imaging showed an SUV max of 8.6, SUVmax/NB ratio of 0.60, and 
an ADC of 1,987 × 10−6 mm2/s. She was classified as low risk and continued 
treatment with tumor treating fields device. She did not progress after 
6 months and was classified as having treatment effect. She is alive and 
without progression of disease at last follow-up 13 months after this 
FDG-PET scan. The top two panels show axial slices of the FDG-PET scan at 
the level of the tumor (left) and normal brain (right). The bottom two panels 
show axial slices of the fluid attenuation inversion recovery at the level of the 
tumor (left) and normal brain (right).
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At last follow-up, 21 patients had died with 20 deaths resulting 
from recurrent tumor and one death from intracranial hemor-
rhage. Median PFS and OS of the entire cohort, measured from 
the baseline FDG-PET scan was 4.9  months [95% confidence 
interval (CI) 1.0–8.7] and 10.7 months (95% CI 7.7–13.7), respec-
tively. The median PFS and OS of the entire cohort, measured 
from the date of the surgery were 17.9 months (98% CI 15–21) 
and 23.7 months (95% CI 21.5–26.2), respectively.
association of imaging and clinical 
Factors with PFs and Os
Baseline MRI was acquired at a median time of 7.5  months 
(range, 0.5–116) after completion of adjuvant chemoradiation. 
Baseline MRI and PET imaging were obtained at suspected first 
progression in 22 patients and second progression in 8 patients.
Imaging and clinical parameters were analyzed in a univari-
ate Cox proportional hazards model (Table 2). Factors included 
MGMT promoter methylation, SUVmean of the enhancing lesion, 
SUVmax/NB index, rCBV, and mean ADC. Mean ADC was calcu-
lated in 28 patients, as there were 2 patients whose images were 
unable to be processed. rCBV was determined for 14 patients 
with available perfusion imaging for analysis. An increased 
SUVmax/NB index, when analyzed as a continuous variable, was 
associated with worse PFS with a hazard ratio (HR) of 1.63 per 
unit increase in index (95% CI 1.10–2.43, p = 0.02) and OS with 
a HR of 4.53 (95% CI 1.10–18.7, p = 0.04). Higher mean ADC, 
analyzed as a continuous variable, trended toward association 
with improved PFS with a HR of 0.998 per 1 ×  10−6  mm2/s 
6Hassanzadeh et al. MRI and PET for Recurrent GBM
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(95% CI 0.997–1.000, p =  0.056) and OS with a HR of 0.998 
(95% CI 0.997–1.000, p =  0.064). MR perfusion parameters 
including rCBV were not significantly associated with PFS or 
OS (p = 0.78 and p = 0.20, respectively). Clinical parameters, 
including patient age, Karnofsky performance score (KPS), 
Radiation Therapy Oncology Group (RTOG) recursive parti-
tioning analysis (RPA) class, surgical extent, other treatment 
before PET scan, and additional treatment after PET scan, were 
not associated with PFS or OS. Female sex was associated with 
improved PFS compared to male sex with a HR of 0.40 (95% CI 
0.17–0.97, p = 0.04) but not overall OS (p = 0.12).
selection of imaging Parameters and 
generation of risk groups
Because the SUVmax/NB index and ADC had significant effects 
on patient OS and PFS, we used these imaging parameters to 
develop a risk stratification system for patients with recurrent 
GBM. We entered these parameters into an ROC analysis for 
identification of optimal thresholds to predict 6-month progres-
sion or treatment effect. An ADC threshold of 1,400 × 10−6 mm2/s 
was identified that had a sensitivity of 76%, specificity of 64%, 
and area under the curve (AUC) of 0.73 (p = 0.04) (Figure S1 
in Supplementary Material). The SUVmax/NB index with an 
optimal threshold of 1.50 had inadequate ROC performance 
with a sensitivity of 33%, specificity of 92%, and AUC of 0.55 
(p = 0.64) (Figure S2 in Supplementary Material). Although not 
significant in the AUC analysis, the SUVmax/NB index threshold 
of 1.50 was retained due to high specificity, and because it was 
found to be highly correlated to PFS (p = 0.01) and OS (p < 0.01). 
Although these individual imaging parameters were not ideal 
predictors of treatment effect by themselves, we hypothesized 
that a composite stratification scheme could be developed that 
leveraged the enhanced sensitivity of ADC and specificity of the 
SUVmax/NB index. We used this composite to determine low, 
intermediate, and high-risk groups for true progression in this 
patient population.
characteristics and clinical Outcomes of 
Patients in risk groups
Using our thresholds for optimal stratification, the low-risk 
category (n  =  11) comprised patients with SUVmax/NB index 
≤1.5 and ADC >1,400 × 10−6 mm2/s. Conversely, the high-risk 
category (n = 7) comprised patients with SUVmax/NB index >1.5 
and ADC ≤1,400 ×  106 mm2/s. The intermediate-risk category 
(n = 11) incorporated all other patients.
Intermediate and high-risk patients were more likely to 
be male compared to low-risk patients (71–75 versus 27%, 
p = 0.047). Patients in the high-risk group were also more likely 
to be treated with bevacizumab prior to their baseline MRI and 
PET scan compared to the intermediate and low-risk groups 
(57 versus 0–18%, p = 0.01). In addition, 45% (5 of 11) patients 
in the low-risk group eventually received additional surgery or 
radiation after the baseline FDG-PET scan while the remaining 
55% (6 of 11) received chemotherapy alone. By contrast, 86% 
(6 of 7) patients in the high-risk group received chemotherapy 
alone, and one patient was observed (p  =  0.03). The groups 
were balanced in the use of bevacizumab after baseline imaging 
(p = 0.79) (Table S1 in Supplementary Material).
The rates of true progression in the low, intermediate, and 
high-risk groups were 36, 67, and 86%, respectively; and the 
frequencies of treatment effect were 64, 33, and 14%, respectively 
(p = 0.04). Of the six patients who received bevacizumab prior to 
baseline imaging, 100% (4 of 4) of patients classified as high risk 
also had true progression while 50% (1 of 2) of patients classified 
as low risk had true progression. Of the 24 patients not previ-
ously treated with bevacizumab, the rates of true progression 
were 33, 67, and 67% in low, intermediate, and high-risk groups, 
respectively. The above associations in the bevacizumab treated 
and not-treated groups were not statistically significant due to 
the diminishing number of patients in subgroups (p = 0.11 and 
p = 0.17, respectively) (Table 3).
The median PFS measured from the date of the FDG-PET 
scan of the low, intermediate, and high-risk groups were 10.0, 
4.4, and 1.9  months, respectively (p =  0.03); and the median 
OS measured from the date of the FDG-PET scan were 23.5, 
10.5, and 3.8 months, respectively (p < 0.01) (Table 3; Figure 2). 
We also identified that the OS measured from the date of surgery 
were significantly different among the risk groups at 32.8, 19.0, 
and 15.4 months (p = 0.047), respectively, among the low, inter-
mediate, and high-risk groups. The differences in PFS between 
the risk groups as measured from the date of surgery were 
20.1, 13.0, and 13.3 months, and were not statistically different 
(p = 0.13) (Figure S3 in Supplementary Material).
DiscUssiOn
Currently, there are no available non-invasive imaging methods 
to easily distinguish between true progression and treatment 
effect. The utility of radiomics in the post-treatment setting 
of GBM has vast implications (25–27). Interestingly, radiom-
ics has shown promise in stratifying patients with GBM into 
short versus long-term survivors (28). Most patients with 
GBM ultimately develop disease progression, but the prob-
lem of determining whether any particular follow-up MRI 
represents the start of disease progression is a question that 
remains a significant unmet need in the field. This question is 
difficult to resolve as most patients who have imaging findings 
suspicious for disease progression often do not receive further 
resection or tissue confirmation. In addition, the increased use 
of bevacizumab and other anti-angiogenic agents has further 
complicated surveillance imaging of GBM by potentially reduc-
ing contrast enhancement and FDG-PET uptake both in viable 
tumor and radionecrosis (29–31). By contrast, prior studies 
have suggested that diffusion characteristics of gliomas are not 
affected by bevacizumab (32). MR perfusion has been shown 
to be helpful but is not always routinely available and also can 
be equivocal (5–7, 24, 33–40). The role of radiomics through 
integrating different imaging parameters may be clinically use-
ful especially in the vulnerable period of post-treatment GBM 
management.
In this retrospective study, we examined whether the 
combination of MRI ADC and FDG-PET parameters may 
be a clinically relevant, and useful tool to improve our ability 
TaBle 3 | Imaging parameters and classification of risk groups.
all patients low risk intermediate risk high risk
sUVmax/nB index ≤1.5 
and aDc >1,400
all other patients sUVmax/nB index >1.5 
and aDc≤1,400
Number of patients n = 30 n = 11 n = 12 n = 7
PeT parameters Mean (range) Mean (range) Mean (range) Mean (range)
SUVmax 9.19 (4.55–20.38) 8.12 (4.55–13.81) 7.54 (5.15–11.63) 13.7 (7.14–20.38)
SUVmin 3.74 (1.40–7.11) 3.84 (1.40–7.11) 3.73 (2.17–5.15) 3.61 (2.28–5.35)
SUVmean 6.94 (3.37–23.00) 5.95 (0.48–10.46) 5.70 (3.72–8.65) 10.66 (6.25–23.00)
MTV 7.19 (0.23–43.66) 9.27 (0.48–40.76) 2.95 (0.23–7.21) 11.23 (0.75–43.66)
TLG 48.76 (1.07–455.33) 49.34 (3.44–219.36) 16.91 (1.07–62.36) 102.45 (4.77–445.33)
SUVmax/NB index 1.61 (0.78–6.70) 1.04 (0.60–1.40) 1.12 (0.60–1.50) 1.90 (1.60–2.00)
Mri parameters Mean (range) Mean (range) Mean (range) Mean (range)
Mean ADC 1,285 (906–1,987) 1,613 (1,457–1,987) 1,100 (906–1,245) 1,085 (974–1,366)
rCBV 2.89 (1.02–4.66) 2.70 (1.02–4.66) 2.81 (1.49–3.70) 4.66 (4.66–4.66)
clinical outcome Median (95% ci) Median (95% ci) Median (95% ci) Median (95% ci)
PFS 4.9 months (1.1–8.7) 10.0 months (2.2–17.8) 4.4 months (0.4–8.3) 1.9 months (1.5–2.3)
OS 10.7 months (7.7–13.7) 23.5 months (NC) 10.5 months (4.9–16) 3.8 months (3.2–4.4)
Tumor determination at 6 months n % n % n % n %
Treatment effect 12 40 7 64 4 33 1 14
Tumor progression 18 60 4 36 8 67 6 86
MTV, metabolic tumor volume (cubic centimeters); TLG, total lesion glycolysis (cubic centimeters); NB, normal brain; ADC, apparent diffusion coefficient (×10−6 mm2/s); rCBV, relative 
cerebral blood volume; PFS, progression-free survival measured from date of FDG-PET scan; OS, overall survival measured from date of FDG-PET scan; NC, not calculable; FDG, 
[18F]fluorodeoxyglucose; PET, positron emission tomography.
Tumor progression is defined as pathological evidence of GBM. Imaging progression of disease on two sequential MRI scans, or death within 6 months after FDG-PET scan. 
Treatment effect is defined as no pathological evidence of GBM, lack of further enlargement of lesion on imaging, and no death from disease for 6 months after FDG-PET scan.
FigUre 2 | Kaplan–Meier survival curves representing (a) progression-free survival (PFS) and (B) overall survival (OS) of the entire cohort measured from date of 
[18F]fluorodeoxyglucose (FDG)-positron emission tomography (PET) scan. Numbers below the survival curve represent the number of patients at risk. Numbers in 
parenthesis represent the number of events prior to the time point.
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to predict true tumor progression versus treatment effect in 
patients with suspected recurrence of GBM. We have identi-
fied cutoff values of a SUVmax/NB index >1.5 and an ADC 
≤1,400 × 10−6 mm2/s that predicted, at suspected recurrence, 
the probability of true progression. These data suggest the 
potential for multiparametric MR and FDG-PET imaging as a 
clinically relevant and easily implemented method that can be 
routinely used in the clinic.
Several studies have evaluated the utility of post-treatment 
FDG-PET tumor-to-normal brain ratios in predicting survival 
in patients with malignant gliomas, including GBM with mixed 
results (40–43). A study by Barker et al. graded FDG-PET scans 
by comparing ROI uptake to the contralateral normal cortex in 
55 patients with recurrent malignant glioma, 39 of which had 
GBM (19). The study reported patients with higher PET scores 
or those with high ratios of uptake in the suspected recurrent 
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lesion had worse survival outcomes than those with lower uptake 
ratios. In particular, the median survival was 10  months in 
patients with a higher FDG-PET uptake in the ROI compared 
to the adjacent cortex, while the median survival was 20 months 
in patients with a lower ROI FDG-PET score compared to the 
adjacent cortex. These median survival lengths are similar to 
the high-risk and intermediate-risk groups in our current study. 
However, in our study, the incorporation of low ADC into the 
stratification scheme with high FDG-PET uptake resulted in 
an even more limited median OS of 3.8  months in high-risk 
groups. In addition, several previously reported studies have 
incorporated multiple glioma histologies (33, 34, 39, 44, 45). 
The limitation in incorporating multiple grades of glioma in a 
single imaging analysis is highlighted in a study by Yoon et al. 
which found significant differences in multiple MRI and FDG-
PET parameters in patients with low- and high-grade gliomas 
(35). Therefore, the different imaging profiles of various glioma 
grades can confound the predictive value of MR and PET imaging 
specific to GBM. Other studies have confirmed that MR imaging 
features, including residual T1 enhancing volume (46), ADC (37, 
38), and relative CBV (36), have been correlated with survival 
outcomes in recurrent GBM.
One of the strengths of this small, retrospective study is 
the integrated model combining MR and FDG-PET imaging 
parameters. Several advantages are gained by combining MR 
and FDG-PET modalities in order to determine patient prog-
nosis after suspected recurrence. First, this is an important area 
of investigation given that MR diffusion imaging along with 
FDG-PET are readily available in most clinical venues and can 
be easily incorporated into routine GBM surveillance imaging. 
By contrast, other promising PET radiotracers such as [18F]-DOPA 
and [18F]-FET (10, 24, 47) may not be widely accessible. Second, 
our study showed the prognostic value of easily attainable and 
measurable parameters to predict patient survival endpoints in 
patients with suspected recurrence of GBM. Third, the study 
population was relatively homogenous with respect to GBM 
histology, the treatment received prior to PET imaging, and the 
reproducibility of the technique used to analyze MR and PET 
imaging.
Prior studies have shown that MGMT promoter methylation 
status, RPA, and possibly female sex are prognosticators for sur-
vival in GBM patients (48–50). Our study confirmed that MGMT 
methylation status and female sex were associated with better PFS 
on univariate analysis. However, we did not observe an associa-
tion between the RTOG RPA class and OS. In addition, we did not 
identify a correlation between age, KPS, or the extent of resection 
with PFS or OS. These observations are likely attributable to the 
small sample size of our study. Interestingly, all patients who were 
classified as high risk that were treated with bevacizumab prior to 
the scans had true recurrence of GBM.
There are also several limitations in our study approach. 
First, the study population is relatively small and derived from 
a retrospective single-institution review. Therefore, our find-
ings need to be validated using a larger dataset in a prospective 
fashion. In addition, significant heterogeneity was present in the 
salvage therapies received by our patients after first recurrence 
and some of the patients had prior progression events. Also, we 
included both patients who received total and STRs that may have 
confounded times to progression. The study also did not have a 
multivariate analysis to assess potential confounders due to the 
small cohort of patients. Association between MR and PET imag-
ing parameters and survival outcomes was significant regardless 
of the salvage regimen administered. True tumor progression at 
the time of imaging was retroactively scored from radiographic 
or clinical progression after further follow-up in most patients. 
Pathology results from surgery or biopsy was also available in 
only a subset of patients.
cOnclUsiOn
We assessed several MR and FDG-PET parameters and their 
association with progression and survival outcomes in patients 
with suspected recurrence of GBM on follow-up MRI scan. Our 
analysis indicates that integrated MR and PET imaging analyses 
may be an important clinically relevant tool to improve our ability 
to distinguish true tumor progression and treatment effect. These 
results require further confirmation in a larger, prospective study.
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FigUre s1 | Receiver-operator characteristic curve of mean apparent diffusion 
coefficient (ADC) in dichotomizing progression versus radionecrosis.
FigUre s2 | Receiver-operator characteristic curve of SUVmax/NB ratio in 
dichotomizing progression versus radionecrosis.
FigUre s3 | Kaplan–Meier survival curves representing (a) progression-free 
survival (PFS) and (B) Overall Survival (OS) of the entire cohort measured from 
date of surgery.
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